Vator Securities advises Sprint Bioscience on 67 MSEK Rights Issue

Comment on transaction


”The implementation of this rights issue is an important step in our ambition of accelerating the development in the company and build shareholder value. I would like to thank new and existing investors for participating in this financing, which will enable the continued development of our current projects and the development of new ones. The company now has its strongest financial position ever considering the partnership with Deciphera and the finalized rights issue. We will be able to broaden our project portfolio and expand the opportunities for new license agreements ", comments Sprint Bioscience CEO, Erik Kinnman.

Press release (in Swedish)

About Sprint Bioscience

Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. Using fragment-based drug discovery, the company develops drug projects in a time- and resource-efficient way. These are then out-licensed to global drug companies during the preclinical phase. The company has successfully entered into several license agreements amounting to a potential value of USD 747 million in milestone payments as well as income from royalties on sales.

The case

• License agreements amounting to a potential value of USD 747 million in milestone payments plus royalties on sales.


• By entering into a license agreement early in the drug development process where the partner finances the continued development of the projects, a broad portfolio with multiple potential revenue streams and diversified risk can be built.


• The current project portfolio consists of three projects out-licensed to global pharmaceutical companies and two internal projects under development.